BlackRock, Inc. Reduces Stake in Aquestive Therapeutics Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, disclosing a reduction in its stake in Aquestive Therapeutics Inc. As of September 30, 2025, BlackRock owns 6,426,343 shares of Aquestive Therapeutics' common stock, representing a 5.3% ownership stake. This marks a significant decrease from its previous holdings, with a reduction of 31,089,275 shares and a value decrease of $36,099,622,559. The filing indicates that BlackRock's ownership is now 5.3% of the total outstanding common shares. The filing also includes certifications that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The amendment was signed by Spencer Fleming, Managing Director of BlackRock, Inc.